Application
Anti-RUNX1 (N-terminal) antibody produced in rabbit is suitable for indirect immunofluorescence and western blot.
Biochem/physiol Actions
RUNX activity is regulated by extracellular signaling pathways resulting in post-translational modifications, such as phosphorylation, acetylation and ubiquitination. It is linked to acute leukemia.
RUNX1 (Runt-related transcription factor 1) plays a vital role in tumour suppression and oncogenic activities. During hematopoiesis, it is involved in hematopoietic development, hematopoietic stem cell homeostasis, and various blood malignancies. It may have clinicopathological impact on the proliferation of human bone marrow cells used for transplantation therapy.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
RUNX1 encodes a DNA-binding subunit.
Runt-related transcription factor 1 (RUNX1) is a transcription factor that plays an important role in hematopoiesis, osteogenesis and neurogenesis. It is a member of Runt-related transcription factors (RUNXs). It was first identified as a component of Polyomavirus enhancer binding protein 2 (PEBP2) and Moloney murine leukemia virus enhancer core binding factor (CBF). Three isoforms of the protein have been identified: RUNX1a, RUNX1b and RUNX1c. Structurally, it consists of Runt domain at the N-terminal region.
Immunogen
synthetic peptide corresponding to amino acids 42-52 of human RUNX1, conjugated to KLH. The corresponding sequence is identical in rat and mouse.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
This product has met the following criteria to qualify for the following awards: